[이코노믹리뷰=황진중 기자] Daewoong Pharmaceutical (069620) announced on the 15th that it recorded 17 billion won in operating profit on a consolidated basis last year. This is a 62% decrease from the previous year. Last year’s sales amounted to 1.55 trillion won, a 5.2% decrease from the previous year, but it achieved sales around 1 trillion won. Net profit fell 12.7% to KRW 25.2 billion.
Daewoong Pharmaceutical explained that the cost of a lawsuit against Medytox related to the botulinum strain and the government’s ban on selling Albis, the gastrointestinal drug, caused extraordinary factors such as a sales gap. Botulinum toxin Nabota sales increased, and prescription drugs and over-the-counter drugs also kept sales.
Nabota sales grew from 44.5 billion won in 2019 to 45.4 billion won last year. Domestic sales nearly doubled. In exports, sales in the US decreased, but were offset by sales in third countries such as Brazil and Thailand.
The prescription drug sector maintained a similar level at 709.4 billion won last year following 7107 billion won in 2019. Albis sales were excluded, but Cresette, Pociga, and Rixiana showed an uptrend. Concor, which started selling newly, also recorded sales of over 10 billion won.
The over-the-counter drug segment grew slightly from 111.8 billion won in the previous year and recorded sales of 1133 billion won this year.
Daewoong Pharmaceutical CEO Jeon Seung-ho said, “Most of the negatives that have adversely affected sales last year have now disappeared.”